There are 2789 resources available
241P - Abemaciclib plus fulvestrant in participants with HR+/HER2- advanced breast cancer: A pooled analysis of the endocrine therapy naïve (EN) participants in MONARCH 2
Presenter: Jose Luis-Gonzalez Trujillo
Session: ePoster Display
242P - Impact of metastases directed radiation therapy on CDK4/6 inhibitors treatment for metastatic breast cancer
Presenter: Icro Meattini
Session: ePoster Display
244P - Real-world first-line treatment patterns and outcomes in hormone-receptor positive advanced breast cancer patients: A multicenter, retrospective study
Presenter: Zhanhong Chen
Session: ePoster Display
246P - Palbociclib dose patterns in Swedish patients with metastatic breast cancer: Evidence from the SIRI study
Presenter: Antonios Valachis
Session: ePoster Display
248P - The implementation of CDK 4/6 inhibitors and its impact on treatment choices in HR+/HER2- advanced breast cancer patients: A study of the Dutch SONABRE registry
Presenter: Marissa Meegdes
Session: ePoster Display
249P - The CDK4/6 inhibitors takeover of the HR+/HER2- locally advanced to metastatic breast cancer market in the EU5: Findings from a real-world study
Presenter: Pierre-Olivier Graff
Session: ePoster Display
250P - Palbociclib: Early treatment-related neutropenia as a potential pharmacodynamic marker?
Presenter: Xenia Fernandez Sala
Session: ePoster Display